Skip to main content
DAEWOONG PHARMA logo

DAEWOONG PHARMA — Investor Relations & Filings

Ticker · 069620 ISIN · KR7069620003 KO Manufacturing
Open in API
Filings indexed 378 across all filing types
Latest filing 2026-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 069620

About DAEWOONG PHARMA

http://crm.daewoong.co.kr/eng/main

Daewoong Pharma is an R&D-centric pharmaceutical company specializing in the development, manufacturing, and commercialization of medical products. The company's portfolio encompasses prescription drugs, with a focus on gastrointestinal and endocrine therapies, alongside biologics, healthcare products, and active pharmaceutical ingredients (APIs). A core tenet of its business model is 'Open Collaboration,' actively seeking partnerships with academic and industry entities to foster innovation. Daewoong Pharma's research efforts are directed towards breakthrough therapies, utilizing advanced drug delivery technologies and expertise in biologics. The company also offers integrated formulation and manufacturing services, supporting partners from initial development to commercial production.

Recent filings

Filing Released Lang Actions
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document is titled “분기보고서 (제25기 1분기)” covering the period 2026-01-01 to 2026-03-31. It contains full business descriptions, financial results, segment disclosures, credit ratings, capital changes, and detailed narrative and quantitative data typical of a quarterly financial report. It is not a short notice or announcement of publication, and it includes substantive financial statements and analysis. Thus it is an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
투자판단관련주요경영사항 (INV008(15PGDH 저해제) 기술도입 계약 체결)
Regulatory Filings Classification · 93% confidence The document is a material agreement announcement (“투자판단 관련 주요경영사항”) disclosing a technology licensing contract, not an earnings release, board change, capital raise, or financial report. It is a routine regulatory announcement required by the stock exchange. It does not contain financial statements or executive certifications, nor is it notifying dividend, proxy, or share issuance. It best fits the catch-all category for general regulatory filings (RNS).
2026-05-12 Korean
영업(잠정)실적(공정공시)
Earnings Release Classification · 89% confidence The document is a Korean “영업(잠정)실적(공정공시)” – a preliminary/fair disclosure of Q1 financial results with key metrics (sales, operating profit, net income) and variance comparisons. It does not contain a full set of financial statements or in-depth analysis characteristic of an interim report, but rather a high-level earnings summary. Therefore it aligns with an Earnings Release (ER). Q1 2026
2026-05-12 Korean
투자판단관련주요경영사항 (mRNA 기반 Epigenetic Reprogramming of Aging (ERA) 기술이전 계약 지위 승계)
Regulatory Filings
2026-05-07 Korean
투자판단관련주요경영사항 (펙수클루정(Fexuclue)의 적응증 추가 국내 품목허가 승인(헬리코박터파일로리 제균을 위한 항생제 병용요법))
Regulatory Filings
2026-04-30 Korean
투자판단관련주요경영사항
Regulatory Filings Classification · 85% confidence The document is a corporate regulatory announcement (Korean “투자판단 관련 주요경영사항”) detailing the company’s IND application for a Phase 3 clinical trial. It is not a financial report (10-K, IR), not an earnings or dividend release, not management changes, nor a share capital notice. It contains substantive disclosure information but is not the report itself nor an investor presentation. Therefore it falls into the fallback category for general regulatory filings.
2026-04-10 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.